Spotlight on JLABS | February 2016

Feb 11 2016https://www.eventbrite.com/e/spotlight-on-jlabs-february-2016-registration-20694...

Come one, come all! You are invited to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in San Diego. JLABS' flagship location currently holds over 40 companies and has several more in the pipeline. Four companies will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS. Don't miss this opportunity to learn more about the progress of this exciting project and meet the companies within JLABS. Please note that the presentations at this event will include publicly available, non-confidential information only.

Date:
Thursday, February 11th, 2016

Agenda:
11:30am | Lunch
12:00pm | Presentations
1:00pm | Program Close

Presenting Companies:
CURx Pharmaceuticals read more»
Batu Biologics read more»
Annam Biosciences, LLC read more»
Biosortia Pharmaceuticals, Inc. read more»

RSVP:
Please RSVP online so that we can get an accurate headcount for food and beverages. We will not be accepting walk-ups once the event is sold out.

Venue:
JLABS
3210 Merryfield Row
San Diego, CA

Presenting Companies' Descriptions:

CURx Pharmaceuticals
We develop therapeutics that are likely to provide effective solutions to currently unmet needs of patients with orphan diseases. Our strategy is to search for and license mid- to late-stage molecules that fulfill our criteria for further development. These criteria include sound scientific rationale, strong preclinical and clinical study results, defined regulatory pathway to approval and robust IP protection.
Web: curxpharma.com

Batu Biologics
Batu Biologics is an immuno-oncology company based out of San Diego, CA dedicated to the development of therapeutics that target the tumor vasculature. Our flagship product, ValloVax, is a multivalent vaccine targeting the tumor endothelium for the treatment of solid tumors. Batu Biologics has currently filed an Investigational New Drug Application (IND) with the US Food and Drug Administration, and anticipates approval in 2016 to initiate a 10 patient Phase I study for non-small cell lung cancer (NSCLC). The company has currently opened a Series A offering asking for $3 Million to fund the Phase I proof of concept study that will help facilitate partnership and acquisition opportunities.
Web: batubiologics.com

Annam Biosciences, LLC
Annam is an early stage specialty biotech company focused on developing oncology products. Their goal is to provide safer, more effective, and more convenient solutions for patients using cancer-targeted medicines. Annam develops proprietary cancer-targeted enhancements to FDA-approved drugs to generate new therapeutic entities. This strategy expedites time for development and approval. The company plans to expand its pipeline of oncology drug candidates using these patent-pending specialty cancer-targeted enhancements with ultra potent anticancer drugs. Annam further seeks to extend the patent life of our products through new intellectual property protection.
Web: annambiosciences.com

Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals is a biopharmaceutical company focused on the development of first-in-class small molecules as potential solutions to high priority unmet medical needs. With proprietary technologies and a team of accomplished scientists, Biosortia has opened the door to a new frontier of fascinating natural products and potential drug candidates. Leveraging Nature for the discovery and development, Biosortia is gaining critical information about chemical interplay and defense mechanism chemistry for potential drugs in the treatment of cancer, CNS disorders, inflammation and infectious diseases. Biosortia's initial leads are already validated by Pharma fueling a quickly emerging pipeline of potential first-in-class drugs.
Web: biosortia.com

Share